Insmed
INSM
157 hedge funds and large institutions have $1.75B invested in Insmed in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 37 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 40
8% less funds holding
Funds holding: 171 → 157 (-14)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
32% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 37
33.81% less ownership
Funds ownership: 144.83% → 111.01% (-34%)
46% less capital invested
Capital invested by funds: $3.24B → $1.75B (-$1.49B)
57% less call options, than puts
Call options by funds: $5.56M | Put options by funds: $13.1M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.6M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$30.9M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$25M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
Top Sellers
INSM Hedge Fund Activity: Q3 2019 in Review
157 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q3 2019, worth a combined $1.75B — down 46% from $3.24B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of INSM and 25 opened new positions — a net loss of 12 holders — while 40 trimmed existing stakes and 62 added.
The largest buyer was Fidelity Investments, adding an estimated $41.6M. The largest seller was Amundi Asset Management US, cutting an estimated $599M.
- 157 institutional investors held Insmed (INSM) as of Q3 2019, down from 171 in Q2 2019.
- Funds reported $1.75B of Insmed stock for Q3 2019, down 46% quarter-over-quarter.
- 25 funds opened new Insmed positions in Q3 2019 and 37 closed out, a net change of -12 holders.
- The largest Insmed buyer in Q3 2019 was Fidelity Investments, an estimated $41.6M added.
- The largest Insmed seller in Q3 2019 was Amundi Asset Management US, an estimated $599M sold.
Based on aggregated 13F filings for Q3 2019.